As of March 31, 2025, the Company had $220.6 million in cash, cash equivalents, and marketable securities, providing expected cash runway into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Is FHTX a Buy, Before Earnings?
- Foghorn Therapeutics Appoints New Board Members
- Foghorn Therapeutics appoints Neil Gallagher, Stuart Duty to board
- Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments
- Foghorn Therapeutics announces new preclinical data at AACR